ARCA biopharma, Inc.

ARCA biopharma, Inc. insiders are currently net sellers of ABIO stock, showing bearish sentiment over the past 90 days. Total sales of $15.2M outpace purchases of $6.8M, creating a net outflow of $8.5M.

ARCA biopharma, Inc. has 39 active insiders who have filed SEC Form 4 transactions in the past 90 days. Funds, Lp Funicular (Executive) leads with 3 transactions totaling $3.5M. Riley Mccormack (Executive) follows with 7 transactions worth $2.5M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. ARCA biopharma, Inc.'s current score of 31/100 indicates bearish insider sentiment. Scores below 40 indicate selling pressure exceeds buying. Insider selling often reflects diversification needs, tax optimization, or estate planning.

The most recent insider transaction occurred on Aug 29, 2024, when Ma-weaver Jacob (Executive) disposed of 6,000 shares at $0.00 per share for $0. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, ABIO insider trading sentiment is currently bearish with an Alignment Score of 31/100. The negative net flow of $8.5M shows more selling than buying. However, 0% of recent transactions are 10b5-1 scheduled trades.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like ARCA biopharma, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At ABIO, we track all Form 4 filings—currently showing 183 transactions from 39 insiders over 90 days.

A 10b5-1 plan allows ARCA biopharma, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At ABIO, approximately 0% of recent transactions are 10b5-1 trades. Most trading activity at ABIO appears discretionary, making insider signals more meaningful.

You can monitor ARCA biopharma, Inc. (ABIO) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 39 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. ARCA biopharma, Inc.'s current score of 31/100 indicates moderately bearish sentiment with selling outpacing buying. This is calculated from $6.8M in purchases versus $15.2M in sales over 90 days, resulting in a net flow of -$8.5M.

SEC Form 4 filings are mandatory reports that ARCA biopharma, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At ABIO, the most common type is "P" with 35 occurrences. The most recent Form 4 was filed on Aug 29, 2024 by Ma-weaver Jacob.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At ARCA biopharma, Inc., approximately 0% of recent transactions are executed under 10b5-1 plans, while 100% appear to be discretionary trades. The low percentage means most insider activity at ABIO represents discretionary decisions with more informational value.